-
Elliott J, Barber PJ, Syme HM, Rawlings JM, Markwell PJ. Feline hypertension: clinical findings and response to antihypertensive treatment in 30 cases. J Small Anim Pract. 2001;42(3):122-129.
-
Henik RA, Snyder PS, Volk LM. Treatment of systemic hypertension in cats with amlodipine besylate. JAAHA. 1997;33(3):226-234.
-
Snyder PS. Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension. JVIM. 1998;12(3):157-162.
-
Snyder PS, Sadek D, Jones GL. Effect of amlodipine on echocardiographic variables in cats with systemic hypertension. JVIM. 2001;15(1):52-56.
-
Geigy CA, Schweighauser A, Doherr M, Francey T. Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate. J Small Anim Pract. 2011;52(7):340-346.
-
Tissier R, Perrot S, Enriquez B. Amlodipine: one of the main anti-hypertensive drugs in veterinary therapeutics. J Vet Cardiol. 2005;7(1):53-58.
-
Helms SR. Treatment of feline hypertension with transdermal amlodipine: a pilot study. JAAHA. 2007;43(3):149-156.
-
Huhtinen M, Derré G, Renoldi HJ, et al. Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats. JVIM. 2015;29(3):786-793.
-
Thomason JD, Fallaw TL, Carmichael KP, Radlinsky MA, Calvert CA. Gingival hyperplasia associated with the administration of amlodipine to dogs with degenerative valvular disease (2004-2008). JVIM. 2009;23(1):39-42.
-
Pariser MS, Berdoulay P. Amlodipine-induced gingival hyperplasia in a Great Dane. JAAHA. 2011;47(5):375-376.
-
Creevy KE, Scuderi MA, Ellis AE. Generalised peripheral oedema associated with amlodipine therapy in two dogs. J Small Anim Pract. 2013;54(11):601-604.
-
Dodd MG, Gardiner DG, Carter AJ, Sutton MR, Burges RA. The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade. Cardiovasc Drugs Ther. 1989;3(4):545-555.
-
Atkins CE, Rausch WP, Gardner SY, Defrancesco T, Keene BW, Levine JF. The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog. J Vet Pharmacol Ther. 2007;30(5):394-400.
-
Brown S, Atkins C, Bagley R, et al. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. JVIM. 2007;21(3):542-558.
-
Steele JL, Henik RA, Stepien RL. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease. Vet Ther. 2002;3(2):157-166.
-
Lefebvre HP, Brown SA, Chetboul V, King JN, Pouchelon JL, Toutain PL. Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des. 2007;13(13):1347-1361.
-
Lefebvre HP, Toutain PL. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther. 2004;27(5):265-281.
-
King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res. 1995;56(12):1620-1628.
-
King JN, Maurer M, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. J Vet Pharmacol Ther. 2003;26(3):213-224.
-
Brown SA, Brown CA, Jacobs G, Stiles J, Hendi RS, Wilson S. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am J Vet Res. 2001;62(3):375-383.
-
Ishikawa Y, Uechi M, Hori Y, et al. Effects of enalapril in cats with pressure overload-induced left ventricular hypertrophy. J Feline Med Surg. 2007;9(1):29-35.
-
Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. JVIM. 2000;14(5):526-533.
-
Brown SA, Finco DR, Brown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res. 2003;64(3):321-327.
-
Kellar KJ, Quest JA, Spera AC, et al. Comparative effects of urapidil, prazosin, and clonidine on ligand binding to central nervous system receptors, arterial pressure, and heart rate in experimental animals. Am J Med. 1984;77(4A):87-95.
-
Long KM, Kirby R. An update on cardiovascular adrenergic receptor physiology and potential pharmacological applications in veterinary critical care. JVECC. 2008;18(1):2-25.
-
Berent AC, Weisse CW, Todd K, Bagley DH. Technical and clinical outcomes of ureteral stenting in cats with benign ureteral obstruction: 69 cases (2006-2010). JAVMA. 2014;244(5):559-576.
-
Haagsman AN, Kummeling A, Moes ME, Mesu SJ, Kirpensteijn J. Comparison of terazosin and prazosin for treatment of vesico-urethral reflex dyssynergia in dogs. Vet Rec. 2013;173(2):41.
-
Quiñones M, Dyer DC, Ware WA, Mehvar R. Pharmacokinetics of atenolol in clinically normal cats. Am J Vet Res. 1996;57(7):1050-1053.
-
Henik RA, Stepien RL, Wenholz LJ, Dolson MK. Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats. J Feline Med Surg. 2008;10(6):577-582.
-
Carlucci L, Song KH, Yun HI, Park HJ, Seo KW, Giorgi M. Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in beagle dogs after oral administration at two dose rates. Pol J Vet Sci. 2013;16(3):555-561.
-
Brown S, Elliott J, Francey T, Polzin D, Vaden S. Consensus recommendations for standard therapy of glomerular disease in dogs. JVIM. 2013;27(Suppl 1): S27-S43.
-
Bugbee AC, Coleman AE, Wang A, Woolcock AD, Brown SA. Telmisartan treatment of refractory proteinuria in a dog. JVIM. 2014;28(6):1871-1874.
-
Sent U, Gössl R, Elliott J, Syme HM, Zimmering T. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. JVIM. 2015;29(6):1479-1487.
-
Axelsson A, Iversen K, Vejlstrup N, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-131.
-
Maille N, Gokina N, Mandalà M, Colton I, Osol G. Mechanism of hydralazine-induced relaxation in resistance arteries during pregnancy: hydralazine induces vasodilation via a prostacyclin pathway. Vascul Pharmacol. 2016;78:36-42.
-
Kittleson MD, Hamlin RL. Hydralazine pharmacodynamics in the dog. Am J Vet Res. 1983;44(8):1501-1505.
-
Miller MW, Adams HR. Drugs acting on the cardiovascular system. In: Riviere JE, Papich MG, eds. Veterinary Pharmacology & Therapeutics. 9th ed. Ames, IA: Wiley-Blackwell; 2009:539-602.
-
Barry DI. Cerebral blood flow in hypertension. J Cardiovasc Pharmacol. 1985;7(Suppl 2):S94-S98.
-
Hunter SL, Culp LB, Muir WW 3rd, et al. Sodium nitroprusside-induced deliberate hypotension to facilitate patent ductus arteriosus ligation in dogs. Vet Surg. 2003;32(4):336-340.
-
Greer RJ, Lichtenberger M, Kirby R. Use of sodium nitroprusside (SNP) for treatment of fulminant congestive heart failure (CHF) in dogs with mitral regurgitation. JVECC. 2004;14(S1):S12 (abstract).
-
Proulx J, Dhupa N. Sodium nitroprusside: uses and precautions. In: Bonagura JD, ed. Kirk’s Current Veterinary Therapy XIII: Small Animal Practice. Philadelphia, PA: WB Saunders; 2000:194-197.